Different treatment modalities have been used according to the cancer subtypes and gene expression profiles including hormonal therapies for hormone receptor-positive (HR+) ( subtypes luminal A and luminal B)3, inhibitors therapy for Her2-enriched BC4, and inhibitors of poly ADP-ribose polymerase (PARP) for triple-negative BC (TNBC) and BRCA1-mutant tumors5. The gene discussed is ERBB2; the disease is cancer.